Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | ACLY | P53396 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ITGA1 | P56199 | 2/20 | 0.55 |
| ▸ | CCR9 | P51686 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528982 | 0.90 | ITGA1 (0.69) | LMNAHTTACLYMAPTALDH1A1 | |
| SCHEMBL27979 | 0.85 | LMNA (0.83) | LMNAHTTACLYMAPTALDH1A1 | |
| SCHEMBL2530071 | 0.85 | LMNA (0.74) | LMNAHTTACLYMAPTALDH1A1 | |
| SCHEMBL2533283 | 0.85 | LMNA (0.64) | LMNAHTTACLYMAPTALDH1A1 | |
| SCHEMBL16715960 | 0.85 | LMNA (0.71) | LMNAHTTMAPTALDH1A1ITGA1 | |
| SCHEMBL2528724 | 0.85 | LMNA (0.64) | LMNAHTTACLYMAPTALDH1A1 | |
| SCHEMBL28006 | 0.84 | LMNA (0.86) | LMNAHTTACLYMAPTALDH1A1 | |
| SCHEMBL33254 | 0.83 | LMNA (0.61) | LMNAHTTACLYMAPTALDH1A1 | |
| SCHEMBL13146494 | 0.83 | LMNA (0.58) | LMNAHTTACLYMAPTALDH1A1 | |
| SCHEMBL27681 | 0.82 | ALDH1A1 (0.61) | LMNAHTTMAPTALDH1A1CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741519-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2008-10-23 | — | — | US | claimed |
| EP-1567486-B1 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX INC (US) | 2008-01-16 | — | — | EP | claimed |
| US-7227035-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX (US) | 2007-06-05 | — | — | US | claimed |
| US-8642808-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110257183-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-10-20 | — | — | US | disclosed |
| US-20100227902-A1 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7741519-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2008-10-23 | — | — | US | disclosed |
| US-7335653-B2 | Chemokine receptor antagonists; CCR9-mediated disorders such as inflammatory and autoimmune diseases | CHEMOCENTRYX, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1567486-B1 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX INC (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070203131-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7227035-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2005112916-A2 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1567486-A2 | BIS-ARYL SULFONAMIDES | Chemocentryx (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050137179-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2004085384-A2 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040167113-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227902-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885ACLY 4326/4885 |
| US-20050137179-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885ACLY 4326/4885 |
| US-20070203131-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885ACLY 4326/4885 |
| US-20040167113-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885ACLY 4326/4885 |
| US-20110257183-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885ACLY 4326/4885 |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | LMNA 4769/4885HTT 3567/4885ACLY 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.